

Striving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. ASCO guidelines list which of the following dosing schedules as preferred when administering GnRHa therapy to appropriately selected patients with HR-positive breast cancer?**
 - a. Monthly**
 - b. 3-monthly
 - c. There is no preference for monthly or 3-monthly GnRH administration
- 2. Which of the following side effects is associated with ovarian function suppression (OFS)?**
 - a. Ocular toxicity
 - b. Alopecia
 - c. Insomnia
 - d. Weight gain
 - e. All of the above**
 - f. None of these
- 3. Of the 497 patients with HR-positive early breast cancer followed for pregnancy status on the POSITIVE trial, approximately what percent had at least one live birth while temporarily discontinuing endocrine therapy to attempt pregnancy?**
 - a. 12%
 - b. 33%
 - c. 45%
 - d. 64%**
- 4. Which of the following best describes results with the addition of OFS to tamoxifen vs tamoxifen alone in premenopausal patients receiving therapy for HR-positive breast cancer in the SOFT/TEXT trials?**
 - a. Increased toxicity with no significant improvement in overall survival (OS)
 - b. Less toxicity with no significant impact on OS
 - c. Increased toxicity with significant improvement in OS**
 - d. Less toxicity with significant improvement in OS
- 5. Which of the following best describes the mechanism of action of fezoline-tant, which is FDA approved for the treatment of vasomotor symptoms due to menopause?**
 - a. Selective serotonin reuptake inhibitor
 - b. Anticonvulsant
 - c. Antihypertensive
 - d. Selective neurokinin-3 receptor antagonist**